Goat F(ab’)2 Anti-Human Ig-BIOT  | 貨號2012-08   規格1.0 mL  (0.5 mg / mL)

產品介紹: Goat F(ab’)2 Anti-Human Ig-BIOT，來源為Pepsin digest of Goat Anti-Human Ig (SB Cat. No. 2010)。特異性辨視of human IgG, IgM, and IgA s之重鏈heavy 、 與輕鏈light chains。此抗體Affinity chromatography on immunoglobulins covalently linked to agarose純化, 具BIOT (Biotin)標誌。可應用於各種免疫分析的試驗。

Specificity	Reacts with the heavy and light chains of human IgG, IgM, and IgA
Source	Pepsin digest of Goat Anti-Human Ig (SB Cat. No. 2010)
Cross Adsorption	None; may react with immunoglobulins from other species
Isotype	Goat F(ab’)2 IgG
Isotype Control	Goat F(ab’)2 IgG-BIOT
Format/Conjugate	BIOT (Biotin)
Buffer Formulation	Supplied in PBS/NaN3
Concentration	0.5 mg/mL
Volume	1.0 mL
Storage & Handling	Store at 2-8°C Please refer to product specific SDS
Applications	Quality tested applications for relevant formats include – ELISA 1,2,5 FLISA Flow Cytometry 7,8 Other referenced applications for relevant formats include – ELISpot 3,4 Immunohistochemistry-Frozen Sections 6 Stimulation 9,10
Recommended Dilutions	Please refer to product specific Technical Bulletin

 

References

1. 1. Kozlowski PA, Chen D, Eldridge JH, Jackson S. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses. 1994;10:813-22. (ELISA)
2. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006;103:17408-13. (ELISA)
3. Sira MM, Yoshida T, Takeuchi M, Kashiwayama Y, Futatani T, Kanegane H, et al. A novel immunoregulatory protein in human colostrum, syntenin-1, for promoting the development of IgA-producing cells from cord blood B cells. Int Immunol. 2009;21:1013-23. (ELISpot)
4. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. (ELISpot)
5. White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014;193:5933-50. (ELISA)
6. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303. (IHC-FS)
7. Heile JM, Fong Y, Rosa D, Berger K, Saletti G, Campagnoli S, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol. 2000;74:6885-92. (FC)
8. Bao G, Li Y, Ma Q, He X, Xing J, Yang X, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther. 2005;4:1374-80. (FC)
9. Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, et al. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013;40:111-21. (Stim)
10. Lyubchenko T, Zerbe GO. B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis. PLoS One. 2014;9(7):e102128. (Stim)